Kymriah (Tisagenlecleucel) for Acute Lymphocytic LeukemiaFebruary 6, 2018
Kymriah is an autologous chimeric antigen receptor (CAR) T-cell therapy that targets the CD19 surface antigen expressed in aggressive B-cell malignancies. It is produced by adapting the patient’s own immune cells with tumor antigen recognition and T-cell activation domains. The process of producing Kymriah begins with collecting peripheral blood mononuclear cells from the patient via leukapheresis. These cells are then sent to a laboratory or a pharmaceutical manufacturing facility where they are genetically engineered to produce CARs on their surface. These reengineered T cells, known as CAR T cells, are able to recognize an antigen on targeted tumor cells. The CAR T cells are next stimulated to multiply. The expanded population of CAR T cells is then prepared for return to a treatment facility where they will be infused back into the patient.
If you have a Hayes login, click here to view the full report on the Knowledge Center.